The authors examined trends in the utilization of prescription opioid medication following introduction of abuse deterrent technology for Oxycontin.
Anthony Palmieri, PharmD, MBA
Advertisement
Articles by Anthony Palmieri, PharmD, MBA
We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
Advertisement
Latest Updated Articles
- The Expanding Role of New Medications in the Treatment of Type 2 Diabetes Mellitus
Published: August 21st 2013 | Updated:
- The Impact of Abuse Deterrent Technologies on Prescription Opioid Trends
Published: October 11th 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Multifaceted Approach to Navigating Career Transitions in Pharmacy
2
FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension
3
First FDA-Approved Oral Liquid Sitagliptin for Adults with Type 2 Diabetes
4
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
5
